Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of YHD1023 in Erectile Dysfunction

Phase 2

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Placebo
Drug: YHD1023
Drug: Cialis

First Posted Date: 2011-08-25

Last Posted Date: 2014-07-31

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 104

Registration Number: NCT01423370

Locations: 🇰🇷
Yuhan Corporation, Seoul, Korea, Republic of

Comparative Pharmacokinetics of YH14659

Phase 1

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: YH14659
Drug: clopidogrel & aspirin

First Posted Date: 2011-08-23

Last Posted Date: 2012-01-09

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 44

Registration Number: NCT01422109

Locations: 🇰🇷
Yuhan Corporation, Seoul, Korea, Republic of

Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pregabalin

First Posted Date: 2011-08-22

Last Posted Date: 2011-08-22

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 28

Registration Number: NCT01420913

Locations: 🇰🇷
Seoul ST.Mary Hospital, Seoul, Korea, Republic of

Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis

Phase 2

Completed

Conditions: Acute Bronchitis
Chronic Bronchitis

Interventions: Drug: YHD001 dose level 1
Drug: YHD001 dose level 2
Drug: Pelargonium sidoides extract
Drug: placebo

First Posted Date: 2011-08-19

Last Posted Date: 2013-09-26

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 118

Registration Number: NCT01420445

Locations: 🇰🇷
The Catholic University of Korea Seoul St. Mary'S Hospital, Seoul, Korea, Republic of

Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044

Phase 1

Completed

Conditions: Premature Ejaculation

Interventions: Drug: dapoxetine

First Posted Date: 2011-08-18

Last Posted Date: 2012-08-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 24

Registration Number: NCT01419470

Locations: 🇰🇷
Samsung medical center, Seoul, Korea, Republic of

Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Placebo
Drug: Bilastine
Drug: Desloratadine

First Posted Date: 2011-07-22

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 239

Registration Number: NCT01400828

Locations: 🇰🇷
Yonsei University college of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of

Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Sequence 2
Other: Sequence 1
Other: Sequence 5
Other: Sequence 3
Other: Sequence 4
Other: Sequence 6

First Posted Date: 2011-04-11

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 30

Registration Number: NCT01332890

Locations: 🇰🇷
ASAN Medical Center, University of Ulsan, Seoul, Korea, Republic of

Bioequivalence Study of Letrozole 2.5 mg Tablets

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Femara (Sequence 1)
Drug: Femara (Sequence 2)
Drug: Peratra (Sequence 2)
Drug: Peratra (Sequence 1)

First Posted Date: 2010-03-10

Last Posted Date: 2019-03-29

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 26

Registration Number: NCT01084499

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: YH4808 400 mg (repeat doses)
Drug: YH4808 600mg
Drug: Esomeprazole 40mg
Drug: YH4808 50mg
Drug: YH4808
Drug: Placebo
Drug: YH4808 30mg
Drug: YH4808 200mg (repeat dose)
Drug: YH4808 100mg
Drug: YH4808 200mg
Drug: YH4808 100mg (repeat dose)
Drug: YH4808 800mg (single dose)

First Posted Date: 2009-11-03

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 134

Registration Number: NCT01007019

Locations: 🇰🇷
Clinical trials center, Seoul national university hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy